

FOR IMMEDIATE RELEASE

February 2, 2016

Listed Company Name: Eisai Co., Ltd.
Representative: Haruo Naito
Representative Corporate Officer and CEO
Securities Code: 4523
Stock Exchange Listings: First Section of the Tokyo Stock Exchange
Inquiries: Sayoko Sasaki
Vice President, Corporate Affairs
Phone +81-3-3817-5120

**Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS)
for the Fiscal Year Ending March 31, 2016**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on May 14, 2015, as follows:

1. Revised full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016)

(Unit: Millions of yen, unless otherwise noted.)

	Revenue	Operating profit	Profit before income taxes	Profit for the period	Basic earnings per share
Previously announced forecast (A) (May 14, 2015)	556,500	46,000	42,800	27,000	93.83 yen
Currently revised forecast (B)	556,500	51,000	49,000	37,000	129.00 yen
Change in amount (B - A)	—	5,000	6,200	10,000	
Percentage of change (%)	—%	10.9%	14.5%	37.0%	
(Reference) Business results for the fiscal year ended March 31, 2015	548,465	28,338	25,875	43,453	151.57 yen

2. Reason for revision of the consolidated financial results forecasts

Due to the high growth of global brands including Halaven, Lenvima and Fycompa, the revenue forecast remains unchanged from the previous forecast of ¥556,500 million (up 1.5% from the previous fiscal year).

Gross profit is forecasted to increase from the previous fiscal year due to increased revenue from the pharmaceutical business. In addition, together with taking measures to improve cost efficiency, Eisai expects gains on sales of investments in subsidiaries as well as non-current assets and has received upfront payments under joint development and promotion agreements toward further streamlining and

concentration of the business. As a result, operating profit is forecasted to be ¥51,000 million (up ¥5,000 million from the previous forecast).

Profit for the period is forecasted to be ¥37,000 million (up ¥10,000 million from the previous forecast), attributable to an increase in operating profit as well as a decline in tax expenses mainly due to transfer price adjustment between Japan and the United States. Furthermore, the forecast for the total dividend for the year remains unchanged at ¥150 per share (same amount as the previous fiscal year).
